WAVE Life Sciences (WVE)
(Delayed Data from NSDQ)
$5.81 USD
-0.19 (-3.17%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $5.81 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
WAVE Life Sciences Ltd. [WVE]
Reports for Purchase
Showing records 1 - 20 ( 57 total )
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Human Genetics Backed INHBE Program is Promising; Reiterate Buy and Raising PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for WVE 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Part A Data Supportive of the Expectations Surrounding Superior Dystrophin Level Going FORWARD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Wave Interferes with Obesity-Our Insights on Inhibin betaE Biology
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
WVE-006 Might Define Wave?s Leadership in RNA Editing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
C9orf72 A Tough Nut to Crack-Thoughts on FOCUS-C9
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Sustained Dystrophin Levels with Longer Exposure of WVE-N531 Might be Key; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Focusing on WVE-N531 With Plans For Harnessing the Power of RNA Medicine; Reit. Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
WAVE Achieves POC Data in the Clinics?Thoughts on WVE-N531?s Trial Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
GSK Eyes On Oligonucleotides Through Wave?s PRISM
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Thoughts on the Upcoming Data Readout of WVE-N531; Reit. Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
RNA Editing, An Early But Compelling Approach in AATD?Initial Thoughts on WVE-006
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Wave''s HD Data Encouraging For the PRISM?Thoughts on the Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Thoughts on WVE-006?The Most Advanced ADAR Program Targeting AATD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
WVE-N531 Update Remains a Central Focus; Reit Buy and Lowering our PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
WVE-004 Demonstrates Target Engagement in Phase 1 ALS/FTD Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Multiple Shots on Goal Across Diverse CNS Pipeline Define 2022; Reiterate Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
With Steady Progress Across Pipeline, We Choose to Focus on WVE-N531; Reit Buy and $10PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A